top of page

We provide a novel cancer immunotherapy technology.

Tokyo Institute of Technology venture


Oct. 5th, 2023 Our president and CEO, Yasuyuki Ishii, spoke at the Tokyo Tech Open innovation.

May. 1st, 2023 We've redesigned our website.

Jan. 15th, 2023 Our headquater has moved with business expansion.

Oct. 4th, 2022 English web page has been opend.

Sep. 1st, 2022 Service web page has been opend.

Jul. 28th, 2022 Accellvecs was certified as Tokyo Tech Venture​ by Tokyo Institute of Technology.

bottom of page